Novo Nordisk stock price forecast: $44.50 support as NVO drops 2.35%

Traders Union
All News
Financial News
Novo Nordisk drops 2.35% today

Highlights

Novo Nordisk's oral Wegovy posted 2.26 billion Danish kroner in first full US quarter sales, reflecting rapid patient uptake.
Amazon completed national Ozempic delivery rollout, expanding US distribution and patient access for Novo Nordisk's key diabetes drug.
Despite operational momentum, technical indicators signal prevailing selling pressure, with $NVO likely to trade sideways between $44.50 and $45.80 next week as further downside risk persists.

Strong demand and access gains as shares face continued pressure

Novo Nordisk reported that oral Wegovy sales in its first full quarter on the US market totaled 2.26 billion Danish kroner, reflecting a significant acceleration in demand and confirming broader patient uptake of the new therapy. Amazon's expansion of Ozempic delivery services was also completed, increasing patient access to Novo Nordisk's diabetes medication through a large e-commerce platform. In addition, the company carried out price reductions in India aimed at adapting to local regulatory and market pressures, which may affect regional profitability. These developments have provided positive operational signals, though price action has remained under broader selling pressure.

Upward bias remains fragile as oscillators diverge near support

On the technical side, NVO is trading above its SMA-20 at $43.27 and SMA-50 at $39.98, but remains under the SMA-200 level of $49.13. Key intraday support is marked by the Ichimoku Kijun at $42.37. Momentum and oscillators are mixed: the MACD and ADX on the daily timeframe indicate a moderate upward bias, while the RSI gives a mild buy signal. However, the Stoch RSI and CCI are neutral, and Bull/Bear Power (BBP) at 0.23 signals oversold conditions, suggesting sellers remain dominant. The price has held near the lower end of today's intraday range with weak rebound attempts, and the Awesome Oscillator remains neutral as oscillators diverge.

Sideways trading likely as downside momentum tempers breakout risk

In the short term, NVO is expected to oscillate within the $44.50 to $45.80 range, a volatility band relative to current levels. With momentum and broader signals pointing predominantly to the downside, the likelihood of a price increase is considered low. The baseline scenario is continued sideways movement within this range. A breakout above $45.80 could prompt an upward move toward prior resistance, while a close below $44.50 would likely trigger additional selling and test the next support levels.

Anton Kharitonov, analyst at Traders Union, sees Novo Nordisk facing a mixed outlook despite strong operational news. He notes solid oral Wegovy sales and broader distribution via Amazon, but points out that technical signals remain weak and price action is pressured below long-term averages. In his view, continued sideways trading between $44.50 and $45.80 is most likely unless a clear break occurs. "I remain cautious here, as downside momentum still dominates despite positive headlines."

Earlier, analysts noted that Novo Nordisk was likely to remain in a period of consolidation amid persistent technical uncertainty and limited breakout potential. Current operational momentum, supported by robust oral Wegovy uptake and expanded distribution channels, underscores the importance of monitoring whether NVO can hold above short-term support, as failure to do so may accelerate near-term downside risk.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.